Matt Gline
CEO of Roivant Sciences
aka Matt Glein
“I think that China is a little bit of a smoke train or a red herring for other dynamics that are changing pretty quickly on the technology side around the commodification of antibody development... if we closed off innovation from China, I think would just happen somewhere else.”
“what does everyone who invents a new drug anywhere in the world want for that drug? They want it to be studied in late stage trials in the US and approved for use here. And to be honest, a lot of that has to do with our high pricing for drugs. But nonetheless it means that innovation around the world winds up benefiting us.”
Matt Gline
One-line summary: Biotech CEO (Roivant Sciences) on the Biotech Hangout roundtable; tracked here for drug-discovery-commoditization and drug-launch/pricing reads.
What they're known for
CEO of Roivant Sciences, a "vant"-model biotech developing multiple assets across affiliated companies; a regular on the Biotech Hangout roundtable. On the July 17 2026 episode his company was preparing to launch brepocitinib (a JAK1/TYK2 oral inhibitor) in dermatomyositis.
Why they matter to stock-market
Gline reframes the "China offshoring" biotech thesis from a geographic story to a technological one — drug discovery (antibodies, some small molecules) is commoditizing globally, and China is merely the current low-cost node. That reframing weakens the "restrict China → protect the US frontier" trade the same way the European-arbitrage counter did, and it independently corroborates the US-market-control lever (high US pricing funds global innovation, so the US sets the rules). His launch/access commentary is also a useful read on orphan-drug pricing dynamics.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On us-biotech-strategic-technology-offshoring:
"I think that China is a little bit of a smoke train or a red herring for other dynamics that are changing pretty quickly on the technology side around the commodification of antibody development... if we closed off innovation from China, I think would just happen somewhere else." — 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026 (2026-07-17)
-
On us-biotech-strategic-technology-offshoring:
"what does everyone who invents a new drug anywhere in the world want for that drug? They want it to be studied in late stage trials in the US and approved for use here. And to be honest, a lot of that has to do with our high pricing for drugs. But nonetheless it means that innovation around the world winds up benefiting us." — 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026 (2026-07-17)
Sources
Related
- us-biotech-strategic-technology-offshoring
- sam-facelli · john-maraganore · yaron-werber — Biotech Hangout co-panelists